Value Asset Creation
Life Sciences value assets.
The strategic document that wins the meeting.
Market intelligence gets you through the door. The asset you bring to the meeting is what wins the mandate. For every high-priority market event, Foresight Bridge creates the strategic document your team walks in with.
Not a capabilities deck. An intelligence-led asset that makes the hiring authority think "this firm understands our problem better than we do."
Also availableHealthcare value assets
Each asset maps to one event archetype.
Regulatory & Quality DistressRemediation Leadership Readiness Brief
- Trigger
- A biopharma company receives an FDA Warning Letter, a CDMO is shut down for cGMP violations, or a MedTech firm faces a Class I recall. The FDA has set a 15-day response deadline or a fixed remediation window, and the board needs to demonstrate leadership change as part of the corrective action plan.
- What it contains
- Quantifies daily revenue loss and pipeline delay cost across the remediation window, shows how peer companies at similar regulatory stage restructured Quality, Regulatory and Manufacturing leadership during comparable enforcement actions, and lays out the 90-day hiring sequence needed to demonstrate adequate corrective action before reinspection: interim VP Quality in week 1-2, permanent VP Quality or Head of Regulatory by week 3-6, Director-level quality systems and validation hires by week 6-12.
- What happens next
- The board reads this and calls you in.
Pipeline Setback & Scientific PivotPipeline Recovery & Scientific Leadership Map
- Trigger
- A clinical trial fails, the FDA issues a Complete Response Letter, or a patent cliff forces a strategic pivot. Pipeline value is frozen, investor confidence is shaken, and R&D leadership must be restructured before the next earnings call.
- What it contains
- Provides a pre-mapped pool of passive CSOs, CMOs, VP R&D and Heads of Clinical Development with track records in the company's pivot area, benchmarks how peer companies restructured R&D leadership after similar setbacks, and identifies the specific appointments that signal scientific credibility to institutional investors.
- What happens next
- The CEO reads this and stops the internal scramble. You get the mandate.
Pipeline Advancement & Commercial Scale-UpGo-to-Market Leadership Blueprint
- Trigger
- A regulatory milestone lands — IND filing accepted, Phase III transition, NDA or BLA filed, 510(k) clearance, PDUFA date approaching. Capital is committed and the hiring window is set by the regulatory clock.
- What it contains
- Maps which roles open at each pipeline stage with exact timing windows — IND acceptance triggers VP Clinical Development within 60 days, Phase III start triggers CCO and VP Market Access within 90 days, PDUFA at 10 months triggers National Sales Director and VP Medical Affairs, 510(k) clearance triggers VP Commercial within 30 days — plus team structure benchmarks from comparable companies and a candidate snapshot showing where the company's offers sit against competitors.
- What happens next
- The CEO reads this and retains you before the first role is posted.
Capital Expansion & Capacity Build-OutCapacity Scale-Up Staffing Blueprint
- Trigger
- Capital is committed to a new facility, production line, or geographic expansion — from a Series B, an IPO, a partnership, or a CDMO capacity win — and the timeline to operational readiness is fixed by construction and validation milestones.
- What it contains
- Maps when to recruit Site Director, VP Manufacturing, Head of Quality and Director of Validation against facility milestones, from groundbreaking through IQ/OQ/PQ validation to first commercial batch. The sequence is modality-specific: a cell therapy facility hires process development leaders 18 months before first batch, a small-molecule plant 12 months out. Includes a modality-matched talent map with geographic concentration data relative to the site.
- What happens next
- The CEO reads this and gives you the full leadership build.
M&A, Ownership Change & PE Platform BuildsPortfolio Integration & Cascade Leadership Map
- Trigger
- A PE firm acquires a CDMO platform, a pharma company completes a bolt-on, or a SPAC merger closes. Integration friction and secondary leadership churn start within 90 days.
- What it contains
- Audits open and at-risk executive seats across every acquired entity — a site-by-site view of each VP, Director and Site Leader: who is staying, who is a flight risk, which roles are already vacant. Predicts the second-wave VP and Director openings arriving 90 to 180 days post-close, and for companies rebuilding after a layoff or pipeline failure, sets out which functions hire first and the profiles that signal turnaround credibility.
- What happens next
- The PE operating partner reads this and gives you the entire portfolio.
Evergreen assets for quiet periods.
When no major market events are firing at a target account, outreach should not stop. Three additional assets keep the conversation alive, adapted for life sciences decision-makers.
- Competitor Talent Vulnerability & Flight-Risk ScorecardWhen a competitor suffers a trial failure, receives a Warning Letter, announces a restructuring, or loses key scientific leadership, their senior talent is destabilised. This asset maps the scientific and operational leaders inside that organisation who are reachable in the next 60 to 90 days, before they land elsewhere.
- Scientific Advisory Board & Board Composition AuditWhen a target enters a new therapeutic area, prepares for an IPO, approaches a PDUFA date or Advisory Committee meeting, or faces a regulatory shift such as EU MDR, their board and SAB may lack the expertise to navigate it. This asset maps the governance gaps and shows how peer companies at the same pipeline stage structured their SABs.
- Offer Acceptance & Compensation DiagnosticWhen a client's internal search stalls on outdated compensation bands or repeated offer rejections, this asset provides the market reality check — real-time data showing where their offers sit, and how peer biotechs at their stage structure equity to close the gap against large pharma packages.
Value Asset Creation is an extension of the intelligence retainer. Tell us your desk and we will show you what the first asset would cover.
Request your free brief